September 29, 2026
Frederick, MD – Jecho Laboratories, Inc. will present emerging preclinical data on JLC068, an affinity-modulated EGFR/TF bispecific antibody-drug conjugate (bsADC) at the 17th Annual World ADC Congress. EGFR and Tissue Factor (TF) are frequently co-overexpressed in solid tumors, including lung, breast, and pancreatic cancers. However, single antigen targeting ADCs have limited efficacy due to antigen heterogeneity and acquired resistance. Jecho has engineered a bsADC with TF-arm attenuation to spare normal tissue and widen the therapeutic window. JLC068 demonstrated robust efficacy across three xenograft models and was well-tolerated at efficacious doses.
The World ADC Congress will be held October 12-15, 2026 in San Diego, CA.
Details on the presentation are below:
JLC068: A Differentiated Affinity-Modulated EGFR/TF Bispecific Antibody-Drug Conjugate
- Abstract Presentation Number: 46
- Session Time: Tuesday, October 13, 2026, 4 – 6 p.m. PST
- Location: Town & Country Resort, San Diego, CA